TME PHARMA N.V.

Analyst Reco. TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Real-time Euronext Paris Other stock markets 03:52:51 2024-04-30 EDT			5-day change	1st Jan Change
0.251 ^EUR	-7.04%		-2.14%	+9.13%

04-25	TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-23	TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Invest Securities Keeps TME Pharma at Buy, Trims PT	04-02	MT
TME PHARMA : Invest Securities slightly adjusts its target	04-02	CF
TME PHARMA : Invest Securities updates its target	11-28	CF
TME PHARMA : Invest Securities confirms its recommendation	23-10-12	CF
Tme Pharma N.V. Announces NOX-A12 Combination Regimen with Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer	23-09-13	CI
TME PHARMA : Invest Securities confirms its recommendation	23-06-28	CF
Appetite for Risk Surges	23-06-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer